Blood test guided treatment for DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been newly diagnosed with diffuse large B-cell lymphoma (DLBCL).
- Before starting treatment, a blood test showed that your tumor DNA (cfDNA) was present in your blood.
- After 6 cycles of R-CHOP chemotherapy, your scans showed that the lymphoma is completely gone (complete remission).
- You have not had a stem cell transplant using your own cells.
- You do not have other cancers (except some skin cancers or cervical cancer), uncontrolled heart disease, or serious infections.
- You are not pregnant, breastfeeding, or have HIV or active hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial tests a way to use your tumor's DNA (called ctDNA) to choose a targeted treatment for your newly diagnosed DLBCL. It aims to see if this personalized approach works better than standard care.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
Hear when a new Lymphoma, Large B-Cell, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.